BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33763357)

  • 1. Systematic Profiling of Alternative Splicing Events in Ovarian Cancer.
    Liu J; Lv D; Wang X; Wang R; Li X
    Front Oncol; 2021; 11():622805. PubMed ID: 33763357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer.
    Zhu J; Chen Z; Yong L
    Gynecol Oncol; 2018 Feb; 148(2):368-374. PubMed ID: 29191436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic characterization of alternative splicing related to prognosis, immune infiltration, and drug sensitivity analysis in ovarian cancer.
    Liu Q; Zhang H; Yang X; Liu X; Yin F; Guo P; Yin Y; Zheng K; Yang Z; Han Y
    Ann Transl Med; 2022 Jan; 10(2):126. PubMed ID: 35282039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative Splicing: A New Therapeutic Target for Ovarian Cancer.
    Yao S; Yuan C; Shi Y; Qi Y; Sridha R; Dai M; Cai H
    Technol Cancer Res Treat; 2022; 21():15330338211067911. PubMed ID: 35343831
    [No Abstract]   [Full Text] [Related]  

  • 5. Alternative splicing acts as an independent prognosticator in ovarian carcinoma.
    Ouyang Y; Xia K; Yang X; Zhang S; Wang L; Ren S; Zhou H; Liu Y; Tang F
    Sci Rep; 2021 May; 11(1):10413. PubMed ID: 34001978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoresistance-associated alternative splicing signatures in serous ovarian cancer.
    Sun T; Yang Q
    Oncol Lett; 2020 Jul; 20(1):420-430. PubMed ID: 32565967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Nomogram With Alternative Splicing Signatures for Predicting the Prognosis of Glioblastoma: A Study Based on Large-Scale Sequencing Data.
    Wang Z; Gao L; Guo X; Feng C; Lian W; Deng K; Xing B
    Front Oncol; 2020; 10():1257. PubMed ID: 32793502
    [No Abstract]   [Full Text] [Related]  

  • 8. Systematic analysis and prediction model construction of alternative splicing events in hepatocellular carcinoma: a study on the basis of large-scale spliceseq data from The Cancer Genome Atlas.
    Yang L; He Y; Zhang Z; Wang W
    PeerJ; 2019; 7():e8245. PubMed ID: 31844595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of Prognostic Alternative Splicing Signature Reveals Recurrence Predictor for Papillary Thyroid Cancer.
    Liu M; Khushbu RA; Chen P; Hu HY; Tang N; Ou-Yang DJ; Wei B; Zhao YX; Huang P; Chang S
    Front Oncol; 2021; 11():705929. PubMed ID: 34722250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma.
    Liu Y; Jia W; Li J; Zhu H; Yu J
    Front Oncol; 2020; 10():587343. PubMed ID: 33117720
    [No Abstract]   [Full Text] [Related]  

  • 11. Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing.
    Zhang D; Zou D; Deng Y; Yang L
    J Ovarian Res; 2021 Sep; 14(1):120. PubMed ID: 34526089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of alternative splicing signature in lung squamous cell carcinoma.
    Yan JQ; Liu M; Ma YL; Le KD; Dong B; Li GH
    Med Oncol; 2021 Mar; 38(5):49. PubMed ID: 33772655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
    Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
    J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive characterization of the alternative splicing landscape in ovarian cancer reveals novel events associated with tumor-immune microenvironment.
    Sun D; Zhao X; Yu Y; Li W; Gu P; Zhi Z; Xu D
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35137909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Genome-Wide Alternative Splicing Profiling and Development of Potential Drugs in Lung Adenocarcinoma.
    Song J; Liu J; Lv D; Meng X; Li X
    Front Genet; 2021; 12():767259. PubMed ID: 34737768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a prognostic alternative splicing signature in oral squamous cell carcinoma.
    Zhang S; Wu X; Diao P; Wang C; Wang D; Li S; Wang Y; Cheng J
    J Cell Physiol; 2020 May; 235(5):4804-4813. PubMed ID: 31637730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
    Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
    J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma.
    Zhang D; Duan Y; Wang Z; Lin J
    Oncol Rep; 2019 Dec; 42(6):2450-2472. PubMed ID: 31578577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic alternative splicing signature reveals the landscape of immune infiltration in Pancreatic Cancer.
    Wang L; Bi J; Li X; Wei M; He M; Zhao L
    J Cancer; 2020; 11(22):6530-6544. PubMed ID: 33046974
    [No Abstract]   [Full Text] [Related]  

  • 20. Comprehensive analysis of prognosis-related alternative splicing events in ovarian cancer.
    Wang S; Wang S; Zhang X; Meng D; Xia Q; Xie S; Shen S; Yu B; Hu J; Liu H; Yan W
    RNA Biol; 2022 Jan; 19(1):1007-1018. PubMed ID: 35980273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.